| __timestamp | Celldex Therapeutics, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 4050200000 |
| Thursday, January 1, 2015 | 4011000 | 5047100000 |
| Friday, January 1, 2016 | 102026000 | 6078400000 |
| Sunday, January 1, 2017 | 96171000 | 6931500000 |
| Monday, January 1, 2018 | 66449000 | 6861900000 |
| Tuesday, January 1, 2019 | 42672000 | 7056300000 |
| Wednesday, January 1, 2020 | 42534000 | 8149300000 |
| Friday, January 1, 2021 | 3068000 | 12310800000 |
| Saturday, January 1, 2022 | 1400000 | 9765700000 |
| Sunday, January 1, 2023 | 3008000 | 8988300000 |
Data in motion
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Viatris Inc. and Celldex Therapeutics, Inc. over the past decade. Viatris, a global healthcare company, consistently reported higher costs, peaking in 2021 with a 205% increase from 2014. In contrast, Celldex, a smaller biotech firm, experienced a 97% decrease in costs over the same period, reflecting strategic shifts and operational efficiencies. The data highlights Viatris's expansive operations compared to Celldex's focused approach. As the industry faces challenges like rising R&D expenses and regulatory pressures, these insights offer a window into how companies manage their financial health. Investors should consider these trends when evaluating potential growth and sustainability in the pharmaceutical sector.
Cost Insights: Breaking Down Zoetis Inc. and Viatris Inc.'s Expenses
Comparing Cost of Revenue Efficiency: GSK plc vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Viatris Inc. vs Bio-Techne Corporation
Cost Insights: Breaking Down Viatris Inc. and BioMarin Pharmaceutical Inc.'s Expenses
Cost of Revenue: Key Insights for Viatris Inc. and Mesoblast Limited
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Geron Corporation
Cost of Revenue Trends: Viatris Inc. vs Dyne Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Walgreens Boots Alliance, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Cytokinetics, Incorporated and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Bausch Health Companies Inc. and Celldex Therapeutics, Inc.